2013 ASCO Annual Meeting: Abstracts Related to RCC
A pre-filtered list of abstracts related to renal cell carcinoma (RCC) from the 2013 Annual Meeting of the American Society of Clinical Oncology, held this week in Chicago.06/01/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 1, 2013 Category: Cancer & Oncology Source Type: news

Over 75s with RCC represent unique subpopulation
Older adults with metastatic renal cell carcinoma are less likely to receive treatment, and have a poorer outcome than their younger peers, research suggests. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - May 24, 2013 Category: Cancer & Oncology Source Type: news

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
Renal cell carcinoma (RCC) is a histopathologically and molecularly heterogeneous disease with the chromophobe subtype (chRCC) accounting for approximately 5% of all cases.05/22/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 22, 2013 Category: Cancer & Oncology Source Type: news

AVEO and Astellas to Present Tivozanib Clinical Data
AVEO Oncology and Astellas Pharma Inc. announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) of investigational agent tivozanib in patients with advanced renal cell carcinoma (RCC) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.05/22/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 22, 2013 Category: Cancer & Oncology Source Type: news

Laparoscopy viable for local RCC relapse
Laparoscopic treatment of local relapse of renal cell carcinoma is a viable alternative to open surgery in selected cases, study findings show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - May 22, 2013 Category: Cancer & Oncology Source Type: news

Promising data for cancer vaccine INTUVAX in the treatment of kidney cancer
Immunicum AB (publ) presents a status update with promising data from an ongoing clinical phase I/II-study of the cancer vaccine INTUVAX™ in the treatment of metastatic renal cell carcinoma. Two patients with poor prognosis have thus far shown an average survival of about 11 months, which can be compared to the expected median survival of 5 months.05/21/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 21, 2013 Category: Cancer & Oncology Source Type: news

NCI Video Series: Understanding Your Cancer Prognosis
Try the Renal Cell Outcome Calculator 05/16/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 16, 2013 Category: Cancer & Oncology Source Type: news

NCI Video Series: Understanding Your Cancer Prognosis
Try the Renal Cell Outcome Calculator 05/16/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 16, 2013 Category: Urology & Nephrology Source Type: news

NCI Video Series: Understanding Your Cancer Prognosis
Try the Renal Cell Outcome Calculator05/16/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 16, 2013 Category: Urology & Nephrology Source Type: news

Bristol-Myers Squibb Advances Leadership Position in Immuno-Oncology
Development program for nivolumab now includes seven potentially registrational trials in non-small-cell lung cancer, advanced melanoma and renal cell carcinoma.05/16/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 16, 2013 Category: Cancer & Oncology Source Type: news

Progression-Free Survival Data for Investigational Afatinib and Nintedanib
Nintedanib is being evaluated in various solid tumors – including advanced NSCLC, ovarian cancer, liver cancer (hepatic cell carcinoma), kidney cancer (renal cell carcinoma) and colorectal cancer.05/16/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 16, 2013 Category: Cancer & Oncology Source Type: news

Statin Use Improved Survival Post-Nephrectomy for RCC
The use of statins was independently associated with improvements in overall survival and disease-specific survival among a group of patients who had undergone partial or radical nephrectomy for renal cell carcinoma. (Source: Cancer Network)
Source: Cancer Network - May 16, 2013 Category: Cancer & Oncology Source Type: news

Statins May Improve Kidney Cancer SurvivalStatins May Improve Kidney Cancer Survival
A new study shows that statin use is associated with a reduced risk for progression after surgery for renal cell carcinoma. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 15, 2013 Category: Consumer Health News Tags: Urology News Source Type: news

Sequential Therapies in Metastatic Renal Cell CarcinomaSequential Therapies in Metastatic Renal Cell Carcinoma
This review presents an evidence-based guide to the sequential therapy options in metastatic renal cell carcinoma. Therapeutic Advances in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 8, 2013 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Cholesterol Drugs Might Boost Kidney Cancer Survival
Cholesterol-lowering statin drugs that are taken by millions of Americans might also improve survival from a type of kidney cancer called renal cell carcinoma, a new study suggests.05/08/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 8, 2013 Category: Cancer & Oncology Source Type: news

Researchers at University of Texas Southwestern Medical Center Describe Findings in Pre-Trial Research
Herein, we report the development and validation of a tumorgraft model of renal cell carcinoma (RCC) and its application to the evaluation of an experimental drug.05/07/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 7, 2013 Category: Cancer & Oncology Source Type: news

Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era
Recent phase III studies of targeted agents for metastatic renal cell carcinoma (mRCC) have generated median survival estimates that far exceed those observed during the cytokine era. However, substantial population-based data does not exist to confirm this trend. We sought to determine whether survival has improved for patients with mRCC diagnosed in the era of targeted therapies, as compared to the era of immunotherapy.05/05/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 5, 2013 Category: Cancer & Oncology Source Type: news

FDA Panel Votes 'No' on Tivozanib for Renal Cancer
The FDA’s Oncologic Drugs Advisory Committee has voted 13 to 1 against AVEO's drug tivozanib for the treatment of patients with metastatic renal cell carcinoma. (Source: Cancer Network)
Source: Cancer Network - May 3, 2013 Category: Cancer & Oncology Source Type: news

Protein Expression of ZEB2 in Renal Cell Carcinoma
ZEB2 has been reportedly shown to mediate the epithelial-to-mesenchymal transition (EMT) and disease aggressiveness in human tumors. However, the expression status of ZEB2 in renal cell carcinoma (RCC) and ZEB2’s clinicopathologic/prognostic significance are poorly understood.05/03/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 3, 2013 Category: Cancer & Oncology Source Type: news

FDA Panel Votes Down Two Cancer Drugs
(MedPage Today) -- SILVER SPRING, Md. -- An FDA advisory committee voiced near unanimous disapproval for a novel advanced renal cell carcinoma drug and a drug-device combo to treat unresectable ocular melanoma that is metastatic to the liver. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 3, 2013 Category: American Health Source Type: news

FDA Panel Says No to Tivozanib in Renal Cell Cancer FDA Panel Says No to Tivozanib in Renal Cell Cancer
FDA's Oncologic Drugs Advisory Committee cites survival signal, poor trial design in decision to recommend against approval. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 2, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

SEER database accurately classified nearly all renal cell carcinoma cases
Shuch B. Urol Oncol. 2013;doi:10.1016/j.urolonc.2012.08.011. (Source: HemOncToday.com)
Source: HemOncToday.com - May 2, 2013 Category: Cancer & Oncology Source Type: news

Laparoscopic radical nephrectomy effective for advanced renal masses
Laparoscopic radical nephrectomy is an effective treatment approach for individuals with renal cell carcinoma who have larger or more advanced renal masses, report researchers. (Source: MedWire News - Urology)
Source: MedWire News - Urology - April 29, 2013 Category: Urology & Nephrology Source Type: news

Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
We retrospectively analyzed metastatic renal cell carcinoma (RCC) patients treated with 3 targeted agents. Patients started the sequence with a tyrosine kinase inhibitor (TKI), sunitinib or sorafenib, and were divided into 2 groups based on the order in which they received the other reciprocal TKI and everolimus (EVE): TKI-TKI-EVE group (n = 19) and TKI-EVE-TKI group (n = 14).04/26/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 26, 2013 Category: Cancer & Oncology Source Type: news

Adrenalectomy for Metastases Benefits Renal-Cancer PatientsAdrenalectomy for Metastases Benefits Renal-Cancer Patients
A retrospective study of more than 300 patients from Europe provides the largest-ever database looking at this issue and suggests renal cell carcinoma patients have the most to gain from this procedure. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 25, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Metastatic renal cell carcinoma agent nearly doubles survival
Results with personalized immunotherapy support phase III study, authors say...04/25/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 25, 2013 Category: Cancer & Oncology Source Type: news

Small renal masses: A positive surgical margin does not affect survival
The incidence and consequences of positive surgical margins after partial nephrectomy are important issues in the management of localized renal cell carcinoma. A recent population-based study demonstrates a slightly higher rate of positive margins...04/24/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 24, 2013 Category: Cancer & Oncology Source Type: news

Renal Cell Tumors More Likely To Metastasize Better Identified By Chemical Shift MRI
Adding "chemical shift" techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients.04/23/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 23, 2013 Category: Cancer & Oncology Source Type: news

Tivozanib's Safety Will Lead The Way Towards Approva
Aveo Pharmaceuticals' (AVEO) big day is getting closer - on May 2nd, the FDA's Oncologic Drugs Advisory Committee (ODAC) is scheduled to review the company's lead drug candidate tivozanib for the treatment of advanced renal cell carcinoma (RCC).04/23/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 23, 2013 Category: Cancer & Oncology Source Type: news

Renal Cell Tumors More Likely To Metastasize Better Identified By Chemical Shift MRI
Adding "chemical shift" techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients. The study, conducted at Massachusetts General Hospital in Boston, included 156 patients with proven renal cell cancer. Clear cell renal carcinoma contains microscopic areas of fat, which is not seen on conventional imaging, said Dr. Azadeh Elmi, lead author of the study. "Chemical shift MRI enables us to quantify even small amounts of fat," she said... (Source: Hea...
Source: Health News from Medical News Today - April 22, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Small Kidney Tumors Potentially Dangerous, Worth Treating
Even those renal cell carcinomas (RCCs) that are smaller than 4 cm may put patients at risk for aggressive cancer, according to a new study presented at the 28th Annual European Association of Urology Congress in Milan, Italy. (Source: Cancer Network)
Source: Cancer Network - April 22, 2013 Category: Cancer & Oncology Source Type: news

Surgery for renal cancer not always needed in elderly individuals
Physicians may want to consider nonsurgical management of patients with localized renal cell carcinoma if they are aged 75 years or more, say researchers. (Source: MedWire News - Urology)
Source: MedWire News - Urology - April 22, 2013 Category: Urology & Nephrology Source Type: news

Multiphasic multidetector CT aids renal cell carcinoma differentiation
Multiphasic multidetector computed tomography may help clinicians discriminate clear cell renal cell carcinoma from oncocytoma, papillary RCC, and chromophobe RCC, study findings suggest. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - April 22, 2013 Category: Cancer & Oncology Source Type: news

Chemical Shift MRI Helps Differentiate Renal Cell Tumors More Likely To Metastasize
Adding “chemical shift” techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients.04/20/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 20, 2013 Category: Cancer & Oncology Source Type: news

Anti-CD70 Immunocytokines for Exploitation of Interferon-γ-Induced RIP1-Dependent Necrosis in Renal Cell Carcinoma
Metastatic renal cell carcinoma (RCC) is an incurable disease in clear need of new therapeutic interventions. In early-phase clinical trials, the cytokine IFN-γ showed promise as a biotherapeutic for advanced RCC...04/19/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 19, 2013 Category: Cancer & Oncology Source Type: news

Anti-CD70 Immunocytokines for Exploitation of Interferon- γ-Induced RIP1-Dependent Necrosis in Renal Cell Carcinoma
Metastatic renal cell carcinoma (RCC) is an incurable disease in clear need of new therapeutic interventions. In early-phase clinical trials, the cytokine IFN- γ showed promise as a biotherapeutic for advanced RCC... 04/19/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 19, 2013 Category: Urology & Nephrology Source Type: news

Chemical shift MRI helps differentiate renal cell tumors more likely to metastasize
(American Roentgen Ray Society) Adding "chemical shift" techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2013 Category: Global & Universal Source Type: news

Retroperitoneal Teratoma With Malignant TransformationRetroperitoneal Teratoma With Malignant Transformation
This interesting report describes a case of papillary renal cell carcinoma in a metastatic testicular germ cell tumor. BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2013 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis
Renal cell carcinoma (RCC) may involve both kidneys. When bilateral nephrectomy is necessary renal replacement therapy is mandatory. Treating such patients with sequential therapy based on cytokines, antiangiogenic factors and mammalian target of rapamycin (mTOR) inhibitors is challenging.04/13/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 13, 2013 Category: Cancer & Oncology Source Type: news

New Cancer Agent Debuts in Multiple CancersNew Cancer Agent Debuts in Multiple Cancers
The investigational agent is being tested in phase 3 trials in 3 different tumor types: melanoma, renal cell carcinoma, and lung cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 8, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cerulean Pharma to Present Data on CRLX101's HIF-1a Inhibition at AACR
Dr. Stephen Keefe to present clinical data demonstrating CRLX101's combinability with Avastin® to treat renal cell carcinoma.04/05/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 5, 2013 Category: Cancer & Oncology Source Type: news

Potential biofluid markers and treatment targets for renal cell carcinoma
In this Review, Wettersten and Weiss discuss novel urinary and blood biomarkers and therapeutic targets for renal cell carcinoma, with the hope that dissemination of this information might lead to clinical utilization.04/03/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 3, 2013 Category: Cancer & Oncology Source Type: news

New Market Study Published: Renal Cell Carcinoma - Pipeline Review
Global Markets Direct's, 'Renal Cell Carcinoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline.04/01/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 1, 2013 Category: Cancer & Oncology Source Type: news

Vasohibin-1 is a new predictor of disease-free survival
Vasohibin-1 (VASH1) is an endothelium-produced angiogenesis inhibitor. Renal cell carcinoma is highly vascularised, but the significance of endogenous VASH1 in renal cell carcinoma has not been defined.03/30/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 30, 2013 Category: Cancer & Oncology Source Type: news

Preoperative CRP Predicts Survival in Renal Cell CarcinomaPreoperative CRP Predicts Survival in Renal Cell Carcinoma
C-reactive protein levels correlated significantly with tumor stage, risk for distant metastasis, and cancer-specific survival, a new study finds. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 27, 2013 Category: Consumer Health News Tags: Urology News Source Type: news

Renal Cell Carcinoma Diagnosed in a Cervical Lymph NodeRenal Cell Carcinoma Diagnosed in a Cervical Lymph Node
This interesting report describes a case of metastasized papillary renal cell carcinoma, primarily diagnosed in a cervical lymph node. BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 27, 2013 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

In Pretreated Advanced Renal Cell Carcinoma, Thought Leaders' Opinions and Clinical Data Indicate that Tivopath Has Efficacy and Tolerability
The report also finds that surveyed oncologists and managed care organization (MCO) pharmacy directors indicate that improved overall survival and progression-free survival are the greatest unmet needs in pretreated advanced renal cell carcinoma. Interviewed thought leaders are optimistic that Bristol-Myers Squibb's nivolumab has the potential to improve overall survival and at least in part address this unmet need.03/27/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 27, 2013 Category: Cancer & Oncology Source Type: news

Cerulean Announces Results from Phase 2b Cancer Trial
CRLX101 is being studied in clinical trials in renal cell carcinoma in combination with Avastin®03/23/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 23, 2013 Category: Cancer & Oncology Source Type: news

Scientists Investigate Potential Markers For A Response To Sunitinib
Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study presented at the 28th Annual EAU Congress currently on-going in Milan.03/22/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 22, 2013 Category: Cancer & Oncology Source Type: news